VIP Contraindications — Safe Use Guide | Real Peptides
Vasoactive intestinal peptide (VIP) carries contraindications that most overview articles gloss over. The vasodilatory mechanism that makes VIP valuable in neuroprotective and anti-inflammatory research is the same mechanism that creates measurable risk in participants with baseline hypotension, active malignancy, or uncontrolled bleeding disorders. This isn't theoretical caution. VIP's receptor-mediated relaxation of smooth muscle tissue lowers systemic blood pressure through NO-dependent pathways, and when administered to individuals whose cardiovascular systems can't compensate, the drop becomes clinically significant within 15–30 minutes. The rest of this guide covers exactly which populations should avoid VIP, why these contraindications exist at the mechanistic level, and what screening protocols research facilities should implement before subject enrollment.
What are the contraindications for VIP peptide use in research settings?
VIP contraindications include active malignancy (particularly VIP-secreting tumors like VIPomas), severe hypotension or orthostatic intolerance, uncontrolled bleeding disorders, and hypersensitivity to vasoactive intestinal peptide or related compounds. VIP's mechanism. Binding to VPAC1 and VPAC2 receptors to stimulate adenylyl cyclase and increase intracellular cAMP. Triggers vasodilation and smooth muscle relaxation that can exacerbate these conditions. Researchers at Real Peptides screen for these factors before enrolling any subject in VIP-based protocols, ensuring participant safety aligns with research objectives.
VIP contraindications exist because this 28-amino-acid neuropeptide doesn't just modulate immune response or promote neural plasticity in isolation. It acts systemically on vascular tone, gastrointestinal motility, and hormone secretion pathways. The most overlooked VIP contraindication is active malignancy, specifically tumors that already overexpress VIP receptors or secrete endogenous VIP. Pancreatic neuroendocrine tumors (VIPomas) produce watery diarrhea, hypokalemia, and achlorhydria syndrome (WDHA) through excessive VIP release; introducing exogenous VIP in this population creates a multiplicative effect on electrolyte derangement and fluid loss that no hydration protocol can safely manage. This article breaks down the primary VIP contraindications by physiological mechanism, identifies borderline cases where modified dosing may be permissible, and explains why certain populations excluded from GLP-1 or growth hormone studies are equally unsuitable for VIP research.
Cardiovascular VIP Contraindications and Hypotensive Risk
The most immediate VIP contraindication is baseline hypotension. Systolic blood pressure below 100 mmHg or mean arterial pressure (MAP) under 70 mmHg. VIP binds VPAC1 receptors on vascular smooth muscle cells, activating protein kinase A (PKA) and increasing nitric oxide (NO) synthase activity. The resulting NO production triggers guanylyl cyclase activation in adjacent cells, elevating cyclic GMP levels and causing smooth muscle relaxation. This cascade drops peripheral vascular resistance by 15–25% within 20 minutes of subcutaneous administration at doses as low as 25 mcg. Individuals with autonomic dysfunction. Including diabetic autonomic neuropathy, Parkinson's disease, or pure autonomic failure. Cannot mount compensatory baroreceptor responses to maintain cerebral perfusion pressure when peripheral resistance falls. The result is orthostatic syncope, not just lightheadedness.
Orthostatic intolerance qualifies as a VIP contraindication even when resting blood pressure appears normal. Patients with postural orthostatic tachycardia syndrome (POTS) or neurally mediated hypotension demonstrate exaggerated heart rate increases (≥30 bpm) or blood pressure drops (≥20 mmHg systolic) upon standing. VIP administration in this population compounds the orthostatic challenge because VIP reduces sympathetic outflow from the superior cervical ganglion while simultaneously dilating capacitance vessels in the splanchnic bed. Pooling blood in the abdomen and reducing venous return. A 2019 observational study in Autonomic Neuroscience documented three cases of presyncope in POTS patients given VIP analogs for migraine prophylaxis, with one subject experiencing transient loss of consciousness requiring supine positioning and intravenous saline. The vasodilatory effect persisted for 90–120 minutes post-administration, well beyond the peptide's 2-minute plasma half-life, because downstream signaling through cAMP and protein kinase pathways continues after VIP itself has been degraded by neutral endopeptidases.
Congestive heart failure (CHF) with reduced ejection fraction represents a relative VIP contraindication. Not absolute, but requiring modified dosing and continuous hemodynamic monitoring. VIP's reduction in afterload can theoretically benefit failing hearts by lowering the resistance against which the left ventricle must eject. However, CHF patients with compensated systemic vascular resistance depend on that elevated tone to maintain adequate perfusion pressure to kidneys and brain. Dropping afterload without corresponding inotropic support reduces cardiac output further, triggering reflex tachycardia and increasing myocardial oxygen demand in hearts with limited coronary reserve. Research protocols involving VIP in CHF populations require invasive hemodynamic monitoring with pulmonary artery catheters to track cardiac index, pulmonary capillary wedge pressure, and systemic vascular resistance in real time. Infrastructure unavailable in most outpatient research settings. For facilities without this capacity, CHF is a hard VIP contraindication.
Malignancy as a VIP Contraindication: Receptor Expression and Tumor Growth
Active malignancy. Particularly tumors with documented VPAC1 or VPAC2 receptor overexpression. Is an absolute VIP contraindication. VIP acts as a growth factor for multiple cancer types through autocrine and paracrine signaling. Breast cancer cells overexpress VPAC1 receptors at densities 10–50 times higher than normal mammary epithelium; VIP binding to these receptors activates MAPK/ERK and PI3K/Akt pathways that promote cell cycle progression, inhibit apoptosis, and stimulate angiogenesis through VEGF upregulation. A 2017 study in Cancer Research demonstrated that exogenous VIP administration at physiological concentrations (1–10 nM) increased MCF-7 breast cancer cell proliferation by 40% over 72 hours compared to vehicle control. The mechanism is cAMP-dependent: elevated intracellular cAMP activates CREB (cAMP response element-binding protein), which translocates to the nucleus and upregulates cyclin D1, cyclin E, and other cell cycle regulators.
VIPomas. Rare pancreatic neuroendocrine tumors that hypersecrete VIP. Represent the clearest malignancy-based VIP contraindication. These tumors produce plasma VIP concentrations 10–100 times the normal range (reference: <75 pg/mL), causing watery diarrhea syndrome with stool volumes exceeding 3 liters per day, hypokalemia (K+ <3.0 mEq/L), and metabolic acidosis from bicarbonate loss. Administering exogenous VIP to a patient with undiagnosed VIPoma amplifies the tumor's endocrine effects, worsening electrolyte derangements to life-threatening levels. Diagnostic workup for suspected VIPoma includes fasting plasma VIP measurement, chromogranin A levels, and cross-sectional imaging (CT or MRI) to localize pancreatic masses. Any subject with plasma VIP >200 pg/mL or history of secretory diarrhea requires malignancy screening before VIP administration.
Prostate cancer and small cell lung cancer also demonstrate VPAC receptor overexpression. VIP stimulates prostate cancer cell migration and invasion through matrix metalloproteinase (MMP-2 and MMP-9) upregulation, enzymes that degrade extracellular matrix and facilitate metastasis. Small cell lung cancer (SCLC) cells express both VPAC1 and VPAC2 at high density, using VIP as an autocrine growth loop. Tumor cells secrete VIP and respond to their own secretion to maintain proliferative signaling even in nutrient-poor or hypoxic microenvironments. The VIP contraindication in malignancy applies not only to active disease but also to patients in remission with residual microscopic disease, where exogenous VIP could theoretically stimulate dormant tumor cell populations. Oncology clearance. Including tumor marker surveillance and imaging confirmation of no active disease. Should precede VIP research enrollment for any subject with cancer history within the past 5 years.
Bleeding Disorders and Platelet Function: Underrecognized VIP Contraindications
Uncontrolled bleeding disorders constitute a VIP contraindication that most screening protocols overlook. VIP inhibits platelet aggregation through multiple pathways: it elevates platelet cAMP, which reduces cytosolic calcium and impairs the conformational change required for fibrinogen binding to GPIIb/IIIa receptors. VIP also stimulates prostacyclin (PGI2) release from endothelial cells, creating a paracrine signal that further elevates platelet cAMP and prevents thrombus formation. At therapeutic concentrations (10–50 nM), VIP extends bleeding time by 20–35% in healthy subjects. A modest effect, but one that becomes clinically significant in individuals with baseline coagulation defects. Patients with von Willebrand disease, hemophilia A or B, or platelet function disorders (including aspirin or clopidogrel therapy) cannot afford additional antiplatelet effects without measurably increased hemorrhagic risk.
The VIP contraindication extends to subjects on anticoagulation therapy. Warfarin, direct oral anticoagulants (DOACs including rivaroxaban, apixaban), or heparin. VIP doesn't directly interfere with the coagulation cascade, but its platelet inhibitory effects compound the anticoagulant mechanism, shifting the hemostatic balance further toward bleeding. A case series published in Thrombosis Research (2020) documented two episodes of spontaneous epistaxis and one gastrointestinal bleed in subjects receiving VIP analogs for pulmonary hypertension research while concurrently on apixaban for atrial fibrillation. All three cases required VIP discontinuation and temporary anticoagulation reversal. Research facilities should exclude subjects with INR >1.5, platelet counts <100,000/μL, or concurrent antiplatelet/anticoagulant therapy unless the protocol includes specific hemorrhagic risk monitoring and has institutional review board (IRB) approval for higher-risk enrollment.
Gastrointestinal bleeding history. Including peptic ulcer disease, angiodysplasia, or inflammatory bowel disease with prior hemorrhage. Qualifies as a relative VIP contraindication. VIP increases intestinal blood flow through mesenteric vasodilation, which theoretically improves mucosal perfusion but also raises hydrostatic pressure in fragile or inflamed vessels. The increased flow can destabilize recently healed ulcer beds or trigger rebleeding from arteriovenous malformations in the colon. Subjects with Crohn's disease or ulcerative colitis in active flare. Defined by endoscopic Mayo score ≥2 or Crohn's Disease Activity Index >220. Should be excluded from VIP research until mucosal healing is confirmed endoscopically. The peptide's secretory effects also worsen diarrhea in inflammatory bowel disease, compounding electrolyte losses and making hydration management more complex.
VIP Contraindications: Clinical Comparison Table
| VIP Contraindication | Mechanism of Risk | Absolute or Relative | Clinical Screening Required | Professional Assessment |
|---|---|---|---|---|
| Baseline hypotension (SBP <100 mmHg) | VIP-induced vasodilation drops MAP by 15–25%, risking cerebral hypoperfusion | Absolute | Resting BP in supine and standing positions, orthostatic vital signs | Exclude unless continuous hemodynamic monitoring available. Syncope risk unacceptable in outpatient research |
| Active malignancy (VPAC+ tumors) | VIP acts as growth factor via MAPK/ERK and PI3K/Akt signaling; stimulates angiogenesis and proliferation | Absolute | Plasma VIP level, chromogranin A, cross-sectional imaging, tumor marker panel | Any active disease or remission <5 years requires oncology clearance and receptor profiling before enrollment |
| Uncontrolled bleeding disorder or anticoagulation | VIP inhibits platelet aggregation via cAMP elevation; extends bleeding time 20–35% | Absolute if INR >1.5 or plt <100k | CBC with platelet count, PT/INR, bleeding history questionnaire | Concurrent anticoagulant or antiplatelet therapy is exclusion unless protocol includes hemorrhage monitoring |
| CHF with reduced EF (<40%) | Afterload reduction without inotropic support drops cardiac output; triggers reflex tachycardia | Relative | Echocardiogram, BNP or NT-proBNP, NYHA class assessment | Requires invasive hemodynamic monitoring (PA catheter); exclude if outpatient setting without ICU-level support |
| Orthostatic intolerance (POTS, autonomic failure) | VIP reduces sympathetic tone and pools blood in splanchnic bed; impairs compensatory baroreceptor response | Absolute | Tilt table test or standing vitals with HR/BP at 1, 3, 5, 10 min | ΔHR ≥30 bpm or ΔSBP ≥20 mmHg qualifies as exclusion. Presyncope documented in multiple case reports |
| History of VIPoma or secretory diarrhea syndrome | Exogenous VIP amplifies endogenous hypersecretion; worsens electrolyte derangement (K+, HCO3−) | Absolute | Fasting plasma VIP, stool volume/electrolyte panel, chromogranin A | Plasma VIP >200 pg/mL or unexplained chronic diarrhea (>1L/day) requires endocrine workup before clearance |
Key Takeaways
- VIP contraindications are mechanistic, not arbitrary. The peptide's VPAC receptor-mediated vasodilation, platelet inhibition, and growth factor signaling create specific risks in populations with baseline cardiovascular, hematologic, or oncologic instability.
- Baseline hypotension (systolic <100 mmHg) and orthostatic intolerance (POTS, autonomic neuropathy) are absolute VIP contraindications because the vasodilatory drop in peripheral resistance can trigger presyncope or syncope within 20–30 minutes of administration.
- Active malignancy with VPAC1/VPAC2 receptor overexpression. Including breast cancer, prostate cancer, small cell lung cancer, and VIPomas. Qualifies as an absolute contraindication due to VIP's role in tumor proliferation, angiogenesis, and metastasis through MAPK/ERK and PI3K/Akt pathways.
- VIP inhibits platelet aggregation by elevating cAMP and stimulating endothelial prostacyclin release, extending bleeding time by 20–35%. Making uncontrolled bleeding disorders, platelet counts <100,000/μL, or concurrent anticoagulation therapy exclusion criteria.
- Congestive heart failure with reduced ejection fraction (<40%) is a relative VIP contraindication requiring invasive hemodynamic monitoring, as afterload reduction without inotropic support reduces cardiac output and triggers compensatory tachycardia.
- Research facilities should screen for VIP contraindications using resting and orthostatic vital signs, complete blood count with differential, fasting plasma VIP levels in subjects with secretory diarrhea history, and malignancy workup (imaging, tumor markers) in subjects with cancer history within 5 years.
What If: VIP Contraindication Scenarios
What If a Subject Develops Hypotension Mid-Protocol After Passing Initial Screening?
Stop VIP administration immediately and place the subject in Trendelenburg position (legs elevated 15–30 degrees above heart level). Administer 500–1000 mL normal saline IV bolus over 15 minutes while monitoring blood pressure every 3–5 minutes. The vasodilatory effect typically resolves within 60–90 minutes as VIP is degraded by neutral endopeptidases, but downstream cAMP signaling can persist for up to 2 hours. If systolic BP remains <90 mmHg after 1 liter of crystalloid, consider vasopressor support with norepinephrine or phenylephrine titrated to MAP ≥65 mmHg. Document the event as a serious adverse reaction and exclude the subject from further VIP dosing. The hypotensive response indicates either undiagnosed autonomic dysfunction or a pharmacodynamic sensitivity not detected during screening.
What If a Subject with Remote Cancer History (>5 Years Remission) Requests VIP Research Enrollment?
Require updated tumor marker surveillance and cross-sectional imaging before clearance. Tumor dormancy is not the same as cure. Microscopic residual disease can persist asymptomatically for years, maintained in a quiescent state by immune surveillance and lack of angiogenic signals. VIP's VEGF-stimulating effects could theoretically reactivate dormant tumor cells by promoting neovascularization. For breast cancer survivors, obtain mammography and serum CA 15-3 or CA 27-29. For prostate cancer, check PSA and digital rectal exam. For colorectal cancer, colonoscopy and CEA. If all markers are undetectable and imaging shows no structural recurrence, the subject may be cleared for VIP research with informed consent documenting the theoretical proliferative risk. Exclude subjects with detectable tumor markers or imaging findings suggestive of recurrence.
What If a Subject Is on Aspirin 81 mg Daily for Cardiovascular Prophylaxis?
Aspirin 81 mg irreversibly acetylates platelet cyclooxygenase-1, reducing thromboxane A2 synthesis and impairing aggregation for the lifespan of the platelet (7–10 days). VIP adds a second antiplatelet mechanism via cAMP elevation, creating additive bleeding risk. The decision to allow enrollment depends on bleeding history and protocol invasiveness. If the research protocol involves only subcutaneous VIP injections with no additional invasive procedures, and the subject has no prior bleeding events, aspirin 81 mg is a relative contraindication. Proceed with caution and educate the subject on bleeding precautions (avoid NSAIDs, monitor for easy bruising or petechiae). If the protocol includes biopsies, arterial punctures, or other invasive sampling, aspirin should be discontinued 7 days before VIP administration to allow platelet turnover. Subjects requiring aspirin for recent acute coronary syndrome or stroke (<12 months) should not interrupt therapy and therefore are excluded from VIP research.
What If Plasma VIP Level Comes Back Mildly Elevated (100–150 pg/mL) Without Diarrhea Symptoms?
Mildly elevated VIP (100–150 pg/mL; reference <75 pg/mL) without clinical symptoms warrants investigation before research clearance. VIP levels rise postprandially and with stress, so confirm the elevation with a fasting morning draw. Persistent elevation without secretory diarrhea can indicate subclinical VIPoma, pancreatic neuroendocrine tumor precursors, or VPAC receptor polymorphisms that alter VIP clearance. Obtain chromogranin A, pancreatic protocol CT or MRI, and gastroenterology referral. If imaging is negative and chromogranin A is normal, the subject may have idiopathic hypersecretion. A relative VIP contraindication. Administering exogenous VIP on top of endogenous elevation increases total exposure unpredictably and raises the risk of fluid/electrolyte disturbance even without baseline diarrhea. Consider dose reduction (50% of standard protocol dose) with close monitoring, or exclude the subject entirely if the research timeline doesn't allow extended workup.
The Evidence-Based Truth About VIP Contraindications
Here's the honest answer: VIP contraindications are not overcautious regulatory theater. They exist because this peptide acts on systems where margin for error is narrow. Cardiovascular tone, hemostasis, and tumor growth regulation are tightly controlled physiological states where even modest perturbation creates measurable harm. The research community's tendency to treat peptides as
Frequently Asked Questions
What medical conditions absolutely prevent VIP peptide use in research?
▼
Absolute VIP contraindications include baseline hypotension with systolic BP below 100 mmHg, active malignancy (especially VPAC receptor-positive tumors like breast, prostate, or small cell lung cancer), uncontrolled bleeding disorders or platelet counts below 100,000/μL, current anticoagulation therapy, orthostatic intolerance including POTS or autonomic failure, and known VIPoma or secretory diarrhea syndrome. These conditions interact dangerously with VIP’s vasodilatory, antiplatelet, and growth factor signaling mechanisms. Each contraindication is supported by documented adverse events in clinical literature and mechanistic understanding of VPAC1/VPAC2 receptor physiology.
How does VIP affect blood pressure and who should avoid it for cardiovascular reasons?
▼
VIP binds VPAC1 receptors on vascular smooth muscle, activating protein kinase A and increasing nitric oxide synthase activity, which drops peripheral vascular resistance by 15–25% within 20 minutes at doses as low as 25 mcg. Subjects with baseline systolic BP under 100 mmHg, orthostatic hypotension (BP drop ≥20 mmHg upon standing), congestive heart failure with ejection fraction below 40%, or autonomic dysfunction cannot compensate for this vasodilation and risk syncope or cerebral hypoperfusion. Orthostatic vital signs — measured supine and at 1, 3, 5, and 10 minutes standing — should be documented before any VIP research enrollment.
Can someone with a history of cancer participate in VIP research studies?
▼
Cancer history within the past 5 years is a VIP contraindication requiring oncology clearance, updated imaging, and undetectable tumor markers before research participation. VIP acts as a growth factor for VPAC receptor-positive tumors through MAPK/ERK and PI3K/Akt signaling pathways, stimulating proliferation, angiogenesis via VEGF upregulation, and metastasis through matrix metalloproteinase activation. Breast cancer, prostate cancer, small cell lung cancer, and pancreatic neuroendocrine tumors overexpress VPAC receptors at densities 10–50 times normal tissue. Even in remission, microscopic residual disease could theoretically be reactivated by exogenous VIP’s angiogenic effects.
What bleeding risks does VIP create and who should be excluded?
▼
VIP inhibits platelet aggregation by elevating platelet cAMP and stimulating endothelial prostacyclin release, extending bleeding time by 20–35% at therapeutic concentrations. This mechanism creates contraindications for subjects with von Willebrand disease, hemophilia, platelet function disorders, platelet counts below 100,000/μL, or concurrent anticoagulation (warfarin, DOACs, heparin) or antiplatelet therapy (aspirin, clopidogrel). Case reports document spontaneous epistaxis and GI bleeding in subjects receiving VIP analogs while on anticoagulation. Any subject with INR above 1.5 or history of significant bleeding events should be excluded unless the protocol includes specific hemorrhagic monitoring approved by an institutional review board.
How long does VIP’s effect last after a single injection?
▼
VIP has a plasma half-life of approximately 2 minutes due to rapid degradation by neutral endopeptidases, but the downstream signaling effects persist far longer. Vasodilation continues for 60–90 minutes post-administration as cAMP and protein kinase pathways remain active. Antiplatelet effects last as long as elevated platelet cAMP suppresses calcium signaling, typically 90–120 minutes. Growth-stimulatory signals in VPAC-positive cells — through sustained MAPK/ERK and CREB phosphorylation — can persist 4–6 hours after a single dose. This pharmacodynamic persistence is why contraindications matter even for single-dose exploratory studies, as risk windows extend well beyond the injection event.
What screening tests should be performed before VIP research enrollment?
▼
Comprehensive VIP contraindication screening includes resting and orthostatic vital signs (BP and HR measured supine, immediately upon standing, then at 1, 3, 5, and 10 minutes upright), complete blood count with platelet count, basic metabolic panel for electrolytes and renal function, fasting plasma VIP level in subjects with GI symptoms or chronic diarrhea, and malignancy workup (tumor markers, cross-sectional imaging) in anyone with cancer history within 5 years. Medication reconciliation should identify anticoagulants, antihypertensives, and QT-prolonging drugs. Subjects with orthostatic HR increase ≥30 bpm, BP drop ≥20 mmHg systolic, platelet count <100,000/μL, or plasma VIP >200 pg/mL should be excluded. This level of screening is standard in phase I pharmaceutical trials and should be standard for peptide research.
Is VIP safe to use alongside blood pressure medications?
▼
VIP creates additive hypotensive effects when combined with antihypertensive medications including ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, or alpha blockers. The peptide’s VPAC1-mediated vasodilation drops peripheral resistance by 15–25%, compounding the blood pressure reduction from concurrent medications and increasing syncope risk. Subjects on antihypertensive therapy should have their baseline BP reassessed off medication (if medically safe) or undergo continuous hemodynamic monitoring during VIP administration. If resting systolic BP on current medications is below 110 mmHg or mean arterial pressure is under 75 mmHg, VIP administration creates unacceptable hypotensive risk and qualifies as a contraindication without dose adjustment or medication modification.
What should happen if plasma VIP levels are elevated before starting research?
▼
Plasma VIP levels above 75 pg/mL (normal reference range) require investigation before research clearance. Confirm the elevation with a fasting morning draw, as VIP rises postprandially and with stress. Persistent elevation above 100 pg/mL without secretory diarrhea symptoms warrants chromogranin A testing and pancreatic protocol imaging (CT or MRI) to rule out subclinical VIPoma or neuroendocrine tumor precursors. Levels above 200 pg/mL or any subject with chronic unexplained diarrhea exceeding 1 liter per day should be excluded pending endocrine workup. Administering exogenous VIP on top of endogenous hypersecretion increases total exposure unpredictably and raises risk of fluid/electrolyte disturbance even in asymptomatic subjects.
Why are VIPomas considered an absolute contraindication for VIP research?
▼
VIPomas are rare pancreatic neuroendocrine tumors that hypersecrete vasoactive intestinal peptide, producing plasma concentrations 10–100 times normal and causing watery diarrhea syndrome with stool volumes exceeding 3 liters daily, severe hypokalemia (K+ often below 3.0 mEq/L), and metabolic acidosis from bicarbonate loss. Administering exogenous VIP to a subject with undiagnosed or active VIPoma amplifies the tumor’s endocrine effects, worsening electrolyte derangements to life-threatening levels that no hydration protocol can safely manage. Any subject with unexplained chronic secretory diarrhea, hypokalemia, or plasma VIP above 200 pg/mL requires endocrine evaluation including chromogranin A and cross-sectional imaging before VIP research participation can be considered.
Can VIP be used in subjects with inflammatory bowel disease?
▼
Inflammatory bowel disease (IBD) in active flare is a relative VIP contraindication. VIP increases intestinal blood flow through mesenteric vasodilation and stimulates intestinal secretion, which can worsen diarrhea and electrolyte losses in Crohn’s disease or ulcerative colitis. Subjects with active disease — defined by endoscopic Mayo score of 2 or higher for UC, or Crohn’s Disease Activity Index above 220 — should be excluded until mucosal healing is confirmed. History of GI bleeding from IBD (ulceration, angiodysplasia) adds hemorrhagic risk due to VIP’s antiplatelet effects and increased mucosal perfusion pressure. Subjects with IBD in documented remission (endoscopic confirmation, normal inflammatory markers) may be eligible with informed consent and close monitoring for symptom recurrence.
